1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
HOB Biotech Group Corp., Ltd. Class A

HOB Biotech Group Corp., Ltd. Class A

SSSE:688656
99.00
CNY
-6.44
(-6.11%)
0.39EPS
246.95P/E
6.15BMarket Cap
Oct 30Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.48
3.22
4.41
5.48
4.7
5.16
5.08
6.25
6.45
6.35
6.7
Basic EPS, GAAP
0.1
0.47
0.88
1.35
1.2
1.4
0.66
0.75
0.59
0.37
0.39
Free Cash Flow per Basic Share
-0.24
0.03
0.44
0.71
0.03
-1.02
-2.57
-1.19
-0.87
-0.02
- -
Dividend per Share
0.03
0.04
0.04
0.88
1.04
0.32
0.55
0.33
0.45
0.33
0.53
Book Value per Share
1.26
1.76
2.81
3.16
4.36
12.21
12.36
12.86
12.88
12.92
13.09
Tangible Book Value per Share
1.25
1.74
2.8
2.92
4.12
12.02
12.16
12.67
12.72
12.74
12.92
Basic Weighted Avg Shares
45
45
46
47
47
62
63
63
62
63
62
Sales/Revenue/Turnover
112
146
201
259
222
318
320
394
402
398
414
Operating Margin (%)
4.19
22.67
29.25
27.32
23.49
27.2
13.34
13.99
11.35
5
7.4
Depreciation Expense
5
7
10
13
15
25
33
40
45
65
- -
Net Income, GAAP
4
21
40
64
57
86
42
47
37
23
24
Effective Tax Rate (%)
- -
13.99
14.04
13.21
13.04
13.05
10.39
16.41
10.31
6.53
6.34
Profit Margin (%)
3.88
14.59
19.93
24.64
25.52
27.13
13
12
9.15
5.82
5.85
Working Capital
-2
16
63
51
95
484
270
192
82
127
160
LT Debt
8
7
6
5
32
5
10
1
10
1
1
Total Equity
57
79
133
150
206
770
779
811
812
820
831
Return on Invested Capital (%)
- -
19.79
31.09
34.16
24.51
15.92
5.16
5.42
4.1
2.78
2.93
Return on Capital (%)
- -
21.85
31
36.93
25.43
16.48
5.27
5.78
4.37
2.81
2.82
Return on Common Equity (%)
- -
31.46
37.86
45.15
31.81
17.66
5.38
5.95
4.54
2.84
2.94

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
46
31
31
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
63
64
Market Capitalization
9,763
7,719
6,147

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
236
228
242
Cash, Cash Equivalents & STI
63
58
65
Accounts Receivable, Net
56
44
57
Inventories
107
112
105
Total Current Liabilities
109
83
82
Payables & Accruals
- -
- -
- -
ST Debt
46
31
31
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
55.93%
0.97%
Free Cash Flow
- -
-1,065.23%
-98.22%
Net Income, GAAP
- -
-9%
-36.96%
Sales/Revenue/Turnover
- -
13.63%
-0.98%
Total Cash Common Dividend
- -
-3.08%
-26.19%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
86
117
104
95
402
2025
78
112
- -
106
398
2026
79
117
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.26
0.11
0.16
0.59
2025
0.03
0.17
- -
-0.05
0.37
2026
- -
0.26
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.41
0.01
0.02
0.45
2025
0.02
0.31
- -
0.01
0.33
2026
- -
0.2
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
John Li
Full Time Employees
546
Sector
Health technology
Industry
Medical specialties
Address
No. 9, Dongyanli Road Suzhou JS China 215009
IPO Date
Jan 13, 2021
Website
hob-biotech.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
HOB Biotech Group Corp Ltd (688656.SS) operates as an innovative in vitro diagnostic company focused on the research, development, production and sales of diagnostic reagents and instruments for allergy and autoimmune diseases. The company provides a range of diagnostic tools including line immunoassays under the BioLINE brand offering 18 panels covering 76 food and inhalant allergens; enzyme-linked immunosorbent assays under the BioLISA brand; and advanced chemiluminescent paramagnetic microparticle immunoassays under the BioCLIA brand detecting 76 single allergens and 10 mix allergens, serving laboratories and hospitals in China across 34 provinces and internationally. Founded in 2009 and headquartered in Suzhou, China, HOB Biotech maintains world-class R&D centers in Suzhou and California, US, alongside an ISO 13485-certified manufacturing facility in Suzhou, positioning it as China's market leader in allergy diagnostics and a rising star in autoimmune diagnostics with over 100 product registration certificates and dozens of patents.